Last reviewed · How we verify

VI-0521 Mid Dose

VIVUS LLC · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

VI-0521 Mid Dose is a Small molecule drug developed by VIVUS LLC. It is currently FDA-approved. Also known as: Phentermine/Topiramate.

VI-0521 is being studied as a potential treatment for obesity, type 2 diabetes, and related conditions in adults and children. In a Phase III clinical trial, VI-0521 was compared to placebo and its single-agent constituents, including topiramate and phentermine, for the treatment of obesity in adults.

At a glance

Generic nameVI-0521 Mid Dose
Also known asPhentermine/Topiramate
SponsorVIVUS LLC
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about VI-0521 Mid Dose

What is VI-0521 Mid Dose?

VI-0521 Mid Dose is a Small molecule drug developed by VIVUS LLC.

Who makes VI-0521 Mid Dose?

VI-0521 Mid Dose is developed and marketed by VIVUS LLC (see full VIVUS LLC pipeline at /company/vivus-llc).

Is VI-0521 Mid Dose also known as anything else?

VI-0521 Mid Dose is also known as Phentermine/Topiramate.

What development phase is VI-0521 Mid Dose in?

VI-0521 Mid Dose is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing